NuGenerex Immuno-oncology, Inc. (NGIO)
NuGenerex Immuno-oncology will go public soon, but the exact IPO date is still unknown.
Stock Price: $8.50 - $9.50
Current IPO price range
| Market Cap | 952.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.63M |
| Shares Out | 105.86M |
| EPS (ttm) | -0.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
NuGenerex Immuno-oncology, Inc. has filed to go public with an IPO on the NASDAQ.
About NGIO
NuGenerex Immuno-oncology is focused on the regulation of the immune system to treat cancer and infectious diseases. To that end, we are developing immunotherapeutic products and vaccines based on our proprietary, patented platform technology, Ii-Key. With the Ii-Key vaccine technology, we are able to activate the immune system against target molecules, whether those targets are tumor associated antigens (TAAs) in cancer cells, or viral or bacterial proteins in infectious disease pathogens. Through our 20+ year history of research and developme... [Read more...]
| Industry Pharmaceutical Preparations | IPO Date Pending |
| CEO Joseph Moscato | Employees 6 |
| Stock Exchange NASDAQ | Ticker Symbol NGIO |